Management of nonvariceal upper gastrointestinal bleeding

Area of Science:

• Gastroenterology
• Internal Medicine
• Clinical Trials

Background:

• Nonvariceal upper gastrointestinal bleeding (NVUGIB) constitutes 80-90% of upper GI bleeds, with 5-10% mortality.
• Causes range from ulcers to rarer conditions like aortoenteric fistulas.
• NVUGIB management differs significantly from variceal bleeding due to unique patient factors and outcomes.

Purpose of the Study:

• To review current clinical trial evidence for managing nonvariceal upper gastrointestinal bleeding.
• To highlight differences in patient characteristics, management strategies, and prognosis compared to variceal bleeding.
• To analyze optimal approaches for resuscitation, risk stratification, and endoscopic interventions.

Main Methods:

• Review of published clinical trials on nonvariceal upper gastrointestinal bleeding.
• Analysis of patient characteristics, causes, and clinical features (hematemesis, melena).
• Evaluation of resuscitation protocols, risk scores (Rockall, Glasgow-Blatchford), and endoscopic therapies (PPIs, clips, thermal methods).

Main Results:

• Successful treatment significantly reduces rebleeding; the majority of patients do not rebleed.
• Risk stratification scores aid in predicting outcomes and guiding endoscopic urgency.
• High-dose proton pump inhibitors (PPIs) pre-endoscopy and endoscopic therapies (clipping, coagulation) are crucial.
• Repeat endoscopy, embolization, or surgery may be needed for persistent bleeding.

Conclusions:

• Nonvariceal upper gastrointestinal bleeding necessitates a management strategy distinct from variceal bleeding.
• Early resuscitation, accurate risk assessment, and timely endoscopic intervention are key to favorable outcomes.
• Evidence supports the use of PPIs and endoscopic therapies to minimize rebleeding and mortality.